Celldex Therapeutics | CLDX - Cash And Equivalent


Celldex Therapeutics reported $36.04M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Celldex Therapeutics USD 36.04M 12.99M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025